Bill’s practice concentrates on patent prosecution, having a particular focus on pharmaceutical products and targets along with other small molecules, including dyes, probes, and binding agents. He leverages experience of the organization setting to supply clients having a business-based, product-driven method of all his IP legal services, such as the proper growth and development of patent portfolios, research reviews of targeted companies and technology, and comparative evaluations of competitive patented technologies. Bill also procures global patent protection for pharmaceutical inventions and concentrates on product protection strategies involving formulations, drug delivery technologies, and dosing methods.
Just before joining the IP team at Mintz, Bill would be a partner within the San Francisco Bay Area office of a big, worldwide law practice. Also, he offered as with-house patent counsel for Tularik Corporation. (now a part of Amgen, Corporation.), a business active in the discovery of compounds for that regulating gene expression.
Earlier Bill labored like a senior research researcher and project leader for FMC Corporation and Dow jones Chemical Company/DowElanco, where his research involved the look and synthesis of small molecule regulators of biological processes. Bill’s doctorate thesis, conducted underneath the direction of Professor Paul A. Bartlett at UC Berkeley, concerned the look and synthesis of transition-condition analogs as inhibitors as peptidases.